EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access · CC BY 4.0

Real-world Evaluation of the Effectiveness of Sinopharm COVID-19 Vaccine Against Symptomatic COVID-19 in an Omicron-Dominant Setting in Mozambique: A Test-Negative, Case-Control Study

Igor Ubisse Capitine iD, Asma Binte Aziz iD, Alvaro Manhiça, Inês Tivane, Absalão Zumba iD, Milton Nhumba, Zamith Rebocho iD, Elias Miquicene, Neusa Nguenha, José Langa, Harshvardhan Shrivastava, Yunkai Yang und 17 weitere

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciaf093 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Igor Ubisse Capitine und 28 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Nacional de Saúde, Maputo, Mozambique. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, COVID-19 Vaccines, Vaccine Efficacy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coalition for Epidemic Preparedness Innovations.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We evaluated the effectiveness of the Sinopharm coronavirus disease 2019 (COVID-19) vaccine, introduced in Mozambique, against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), prevalent from March 2022 to December 2023.

Methods

A test-negative case-control study was nested in a community-based enhanced COVID-19 surveillance in seven healthcare facilities including mobile testing stations in the Dondo District, Mozambique, between March 2022 and December 2023. Participants were individuals aged ≥2 years with COVID-19–like symptoms for <10 days. Cases were those with polymerase chain reaction (PCR)–confirmed COVID-19. For each case, three PCR test–negative controls were matched, according to age (±5 years), sex, and date of PCR test (±7 days). Follow-up for all cases was conducted until disease resolution. Vaccine protection was assessed according to the association between complete vaccination and SARS-CoV-2 disease onset ≥14 days after vaccination.

Results

The study did not reach the targeted sample size, and only a third were analyzed. A total of 253 cases were matched to 759 test-negative controls by age, sex, and testing date, a process known as matching. Among cases, 41% had one dose of Sinopharm, 53% had two doses, and 6% were unvaccinated. Among the test-negative controls, 37% had 1 dose, 57% had two doses, and 7% were unvaccinated. The adjusted vaccine effectiveness, calculated using matching and adjusted for age and PCR test date, was 18.0% (95% confidence interval, −85.3 to 63.7; P = .63). No COVID-19–positive participants required hospitalization.

Conclusions

In an Omicron-dominant setting, two doses of the Sinopharm vaccine did not show significant protection against symptomatic COVID-19. However, as our analysis was based on data from only a third of enrolled individuals with confirmed vaccination status, these findings should be interpreted with caution. Our results underscore the importance of real-time vaccine effectiveness evaluations to inform optimal rollout strategies in low- and middle-income countries.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2COVID-19 VaccinesVaccine EfficacyHumansMozambiqueMaleCase-Control StudiesFemaleAdultMiddle AgedAgedYoung AdultAdolescent

Stichwörter der Autor:innen

COVID-19 vaccinationMozambiqueSinopharmeffectivenesstest-negative design (TND)

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Instituto Nacional de Saúde, Maputo, Mozambique.
  • International Vaccine Institute, Seoul, Republic of Korea.
  • Sofala Provincial Delegation, Instituto Nacional de Saúde, Mozambique.
  • China National Biotec Group Company Limited, China.
  • Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar.
  • Department of Epidemiology, University of Washington, Seattle, Washington, USA.

ORCID-Profile: Igor Ubisse Capitine, Asma Binte Aziz, Absalão Zumba, Zamith Rebocho, Ju Yeon Park, Young Ae You, Eun Lyeong Park, Jonathan D Sugimoto, Hyon Jin Jeon, Tabea Binger, Ilesh V Jani, Florian Marks, Birkneh Tilahun Tadesse

Förderung

  • Coalition for Epidemic Preparedness Innovations

Zitieren

APA

Capitine, I. U., Aziz, A. B., Manhiça, A., Tivane, I., Zumba, A., Nhumba, M., Rebocho, Z., Miquicene, E., Nguenha, N., Langa, J., Shrivastava, H., Yang, Y., Wang, S., Park, J. Y., Kyung, S. E., You, Y. A., Lee, H., Park, E. L., Rakotozandrindrainy, R., …, & Tadesse, B. T. (2025). Real-world Evaluation of the Effectiveness of Sinopharm COVID-19 Vaccine Against Symptomatic COVID-19 in an Omicron-Dominant Setting in Mozambique: A Test-Negative, Case-Control Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf093

Vancouver

Capitine IU, Aziz AB, Manhiça A, Tivane I, Zumba A, Nhumba M, et al. Real-world Evaluation of the Effectiveness of Sinopharm COVID-19 Vaccine Against Symptomatic COVID-19 in an Omicron-Dominant Setting in Mozambique: A Test-Negative, Case-Control Study. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf093

BibTeX
@article{Capitine2025,
  author = {Capitine, Igor Ubisse and Aziz, Asma Binte and Manhiça, Alvaro and Tivane, Inês and Zumba, Absalão and Nhumba, Milton and Rebocho, Zamith and Miquicene, Elias and Nguenha, Neusa and Langa, José and Shrivastava, Harshvardhan and Yang, Yunkai and Wang, Shiyu and Park, Ju Yeon and Kyung, Seung Eun and You, Young Ae and Lee, Hyoryoung and Park, Eun Lyeong and Rakotozandrindrainy, Raphaël and Kyoung Jo, Sue and Sherliker, Chloe and Sugimoto, Jonathan D and Jeon, Hyon Jin and Binger, Tabea and Siribie, Mohamadou and Kim, Deok Ryun and Jani, Ilesh V and Marks, Florian and Tadesse, Birkneh Tilahun},
  title = {Real-world Evaluation of the Effectiveness of Sinopharm COVID-19 Vaccine Against Symptomatic COVID-19 in an Omicron-Dominant Setting in Mozambique: A Test-Negative, Case-Control Study},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciaf093}
}
Kostenlos starten →